The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients
Vascular inflammation can be detected in the pericoronary adipose tissue (PCAT) by coronary computed tomography angiography (CCTA) attenuation. Treatment with liraglutide is associated with anti-inflammatory effects and reduces cardiovascular risk in diabetic patients. This study is aimed at examini...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2023/5126825 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850211839461294080 |
|---|---|
| author | Irmelin I. A. Biesenbach Laurits J. Heinsen Katrine S. Overgaard Thomas R. Andersen Søren Auscher Kenneth Egstrup |
| author_facet | Irmelin I. A. Biesenbach Laurits J. Heinsen Katrine S. Overgaard Thomas R. Andersen Søren Auscher Kenneth Egstrup |
| author_sort | Irmelin I. A. Biesenbach |
| collection | DOAJ |
| description | Vascular inflammation can be detected in the pericoronary adipose tissue (PCAT) by coronary computed tomography angiography (CCTA) attenuation. Treatment with liraglutide is associated with anti-inflammatory effects and reduces cardiovascular risk in diabetic patients. This study is aimed at examining the effect of clinically indicated liraglutide on PCAT attenuation. Asymptomatic patients with type 2 diabetes mellitus (T2DM) and without known ischemic heart disease underwent clinical examination, blood analysis, and CCTA. The main coronary arteries were outlined and PCAT attenuation was measured on the proximal 40 mm. Patients treated with liraglutide on a clinical indication were compared to patients not receiving liraglutide. The study included 190 patients; 53 (28%) received liraglutide (Lira+) and 137 (72%) did not (Lira-). There were no significant differences in PCAT attenuation between the two groups in either artery. However, PCAT attenuation measured around the left anterior descending artery (LAD) was lower in the Lira+ group after adjustment for age, sex, body mass index, and T2DM duration (b coefficient -2.4, p=0.029). In a population of cardiac asymptomatic T2DM patients, treatment with clinically indicated liraglutide was not associated with differences in PCAT attenuation compared to nonliraglutide treatment in the unadjusted model. An association was seen in the adjusted model for the left anterior descending artery, possibly indicating an anti-inflammatory effect. |
| format | Article |
| id | doaj-art-8fae0431d5874c96bc50957e211bb71b |
| institution | OA Journals |
| issn | 1755-5922 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-8fae0431d5874c96bc50957e211bb71b2025-08-20T02:09:28ZengWileyCardiovascular Therapeutics1755-59222023-01-01202310.1155/2023/5126825The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic PatientsIrmelin I. A. Biesenbach0Laurits J. Heinsen1Katrine S. Overgaard2Thomas R. Andersen3Søren Auscher4Kenneth Egstrup5Faculty of Health ScienceCardiovascular Research UnitCardiovascular Research UnitCardiovascular Research UnitCardiovascular Research UnitFaculty of Health ScienceVascular inflammation can be detected in the pericoronary adipose tissue (PCAT) by coronary computed tomography angiography (CCTA) attenuation. Treatment with liraglutide is associated with anti-inflammatory effects and reduces cardiovascular risk in diabetic patients. This study is aimed at examining the effect of clinically indicated liraglutide on PCAT attenuation. Asymptomatic patients with type 2 diabetes mellitus (T2DM) and without known ischemic heart disease underwent clinical examination, blood analysis, and CCTA. The main coronary arteries were outlined and PCAT attenuation was measured on the proximal 40 mm. Patients treated with liraglutide on a clinical indication were compared to patients not receiving liraglutide. The study included 190 patients; 53 (28%) received liraglutide (Lira+) and 137 (72%) did not (Lira-). There were no significant differences in PCAT attenuation between the two groups in either artery. However, PCAT attenuation measured around the left anterior descending artery (LAD) was lower in the Lira+ group after adjustment for age, sex, body mass index, and T2DM duration (b coefficient -2.4, p=0.029). In a population of cardiac asymptomatic T2DM patients, treatment with clinically indicated liraglutide was not associated with differences in PCAT attenuation compared to nonliraglutide treatment in the unadjusted model. An association was seen in the adjusted model for the left anterior descending artery, possibly indicating an anti-inflammatory effect.http://dx.doi.org/10.1155/2023/5126825 |
| spellingShingle | Irmelin I. A. Biesenbach Laurits J. Heinsen Katrine S. Overgaard Thomas R. Andersen Søren Auscher Kenneth Egstrup The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients Cardiovascular Therapeutics |
| title | The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients |
| title_full | The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients |
| title_fullStr | The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients |
| title_full_unstemmed | The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients |
| title_short | The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients |
| title_sort | effect of clinically indicated liraglutide on pericoronary adipose tissue in type 2 diabetic patients |
| url | http://dx.doi.org/10.1155/2023/5126825 |
| work_keys_str_mv | AT irmeliniabiesenbach theeffectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT lauritsjheinsen theeffectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT katrinesovergaard theeffectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT thomasrandersen theeffectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT sørenauscher theeffectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT kennethegstrup theeffectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT irmeliniabiesenbach effectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT lauritsjheinsen effectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT katrinesovergaard effectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT thomasrandersen effectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT sørenauscher effectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients AT kennethegstrup effectofclinicallyindicatedliraglutideonpericoronaryadiposetissueintype2diabeticpatients |